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Background: Human breast cancer represents a significantly heterogeneous disease. Global gene expression
profiling measurements have been used to classify tumors into multiple molecular subtypes. The capacity to define
subtypes of breast tumors provides a framework to enable improved understanding of the mechanisms of breast
oncogenesis, as well as to provide opportunities for improved therapeutic intervention in patients.
Methods: We used publicly available gene expression profiling data to identify ‘estrogen independent’ genes in
estrogen receptor alpha (ER+) breast tumors, and subsequently identified 6 subgroups of ER + breast tumors.
Results: Each of the 6 identified subgroups exhibited distinct clinical behaviors and biology. Patients whose tumors
comprised subgroups 2,5&6 experienced excellent long-term survival, whereas those patients whose tumors
belonged to subgroups 1&4 experienced much poorer survival. Breast tumor cell lines representative of the different
subgroups responded to therapeutic compounds in accordance with their subgroup classification.
Conclusions: These data support the existence of 6 distinct subgroups of ER + breast cancer and suggest that
knowledge of the ER + subgroup status of patient samples have the potential to guide therapy choice.
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There is significant molecular and cellular diversity among
human breast tumors. Indeed, this heterogeneity is evident
from histopatholologic features and differences in ER,
progesterone receptor (PR) and ERBB2/HER2/NEU status
as well as more recent molecular classification schemes
based on the expression of large numbers of genes [1-3].
Importantly, these data indicate that breast cancer is an
imprecise definition that embodies many molecularly dis-
tinct neoplastic disorders that share a common normal
breast tissue origin.
The capacity to more accurately define breast cancers
and identify tumor subgroups that represent more homo-
geneous disease entities, provides a framework to increase
our understanding of these diseases and provides oppor-
tunities to focus treatment options for patients. To this* Correspondence: hassell@mcmaster.ca
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article, unless otherwise stated.end investigators have completed relatively large gene ex-
pression studies and identified patterns in gene expression
that reproducibly stratify breast tumors into each of 5 mo-
lecular subtypes. These breast cancer subtypes named
basal-like, ERBB2-positive, normal-like, luminal A and lu-
minal B were originally described by Perou et al. [1]. The
various molecular subtypes possess distinct clinical behav-
iors thus providing a basis for improved taxonomy for
breast cancer. For example, basal-like tumors are highly
aggressive, resistant to endocrine therapies but sensitive to
conventional chemotherapy, whereas luminal A tumors
are more indolent and responsive to endocrine therapies.
Importantly, recent and more comprehensive molecular
profiling of human breast tumors, including global gene
expression, mutation, DNA copy number variation, and
protein expression support the original finding that breast
cancer falls into major molecular subtypes comprising
subsets of genetic and epigenetic abnormalities [4]. Cur-
rently, the additional clinical value of molecular classifica-
tion over traditional histopathological methods is unclear,entral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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the expression of ER, PR, and HER2, as well as to tumor
grade [3].
It is possible that further refinement of the ‘intrinsic’
classification scheme of Perou et al., could identify other
molecular classes of breast cancer, and provide additional
clinical value beyond traditional techniques. For example,
ER + tumors generally fall into the luminal A and B mo-
lecular subtypes, characterized by expression of the ER as
well as cytokeratins typically expressed by luminal epithe-
lial cells [1,3]. However, more recent studies suggest that
as many 12 molecular subgroups of ER + breast cancer
exist, demonstrating that the luminal A and B stratifica-
tion of ER + breast tumors does not fully capture the bio-
logical complexity of these tumors [5]. Indeed, further
dissection of ER + breast tumors into additional relevant
disease subgroups would likely provide further insight into
the mechanisms that underlie these tumors, as well as
prevent carefully planned studies from being confounded
by the heterogeneity found among un-grouped or sub-
optimally grouped populations of ER + breast tumors.
Notably, the molecular subtypes of breast cancer show
subtype specific response to standard chemotherapies as
well as experimental compounds, highlighting the value of
investigating specific disease subtypes [6]. Hence, the iden-
tification and characterization of additional subgroups of
ER + breast tumors could focus treatment options for pa-
tients with ER + breast tumors, because therapy could be
rationally applied based on specific molecular characteris-
tics of the patient’s tumor.
We hypothesized that the biology of ER + tumors
comprised both estrogen-dependent and -independent
components, and furthermore, that investigation and
characterization of the estrogen independent component
might provide a means to stratify ER + tumors into differ-
ent distinct disease subgroups. To this end we used pub-
licly available data to identify ‘estrogen independent’ genes
in ER + breast tumors and subsequently identified sub-
groups of ER + tumors based on molecular differences be-
tween tumors identified by these genes. Importantly, we
reproducibly identified 6 subgroups of ER + breast tumors
that exhibited distinct clinical behavior as well as biology.
Moreover, we show that these subgroups have specific re-
sponses to therapeutic compounds in vitro. Taken to-
gether these data support the existence of 6 distinct
subgroups of ER + breast cancer, and advance efforts to in-
crease the precision of therapeutic intervention in human
breast cancer patients.
Methods
Human breast tumor data sets
All tumor samples were downloaded from the gene
expression omnibus (GEO, http://www.ncbi.nlm.nih.gov/
geo/). The latter included Letrozole treated tumor samples(GSE5462) [7], the discovery cohort (GSE6532, 133A array
samples, n = 327 [8], the validation cohort (GSE6532 133
Plus 2.0 array samples n = 87 [8], GSE9195 n = 77 [9],
GSE17705 n = 298 [10], GSE2034 n = 209 [11], GSE7390
n = 134 [12], Original samples from GSE26971 (n = 136)).
Cell line expression profiles were downloaded from
ArrayExpress (E-TABM-157) [13]. Raw data files repre-
senting the tumor samples were normalised using RMA
[14]. TCGA gene expression was obtained from the
TCGA research network (http://cancergenome.nih.gov/.),
by downloading level 3 RNAseq data from the TCGA data
portal (RSEM normalised) [15]. For GEO cohorts, ER +
status was obtained from associated clinical files, which
were generally based on histopathological assessment.
ER + status for the TCGA cohort was determined using
expression cut-offs (250 RSEM normalised transcript
counts) for the ESR1 gene. ER + patients were selected
from each dataset, and validation cohorts were combined
after each probe set/gene was standardized and mean
centered.
Cell line drug sensitivity data
We obtained previously reported human breast tumor
cell line sensitivity data from Heiser et al. [6].
Definition of estrogen independent genes
We calculated within (w, treatment pairs) and between
(b, independent primary tumor samples) variation for all
tumors. In this fashion probe-sets with greater variation
in expression between tumors than between treatment
paired samples received high b/w scores, and vice versa.
PAM 50 subtype assignment
Subtype membership was assignment was based on the
nearest PAM50 centroid (Pearson correlation) [16].
Class discovery
Non-negative matrix factorization was carried out as
previously described [17]. Prediction analysis of microar-
rays (PAM) was carried out as described [18] to discover
subgroup specific genes (discovery cohort) and to clas-
sify samples (validation cohort, cell lines).
Cell growth assays
All cell lines were obtained from the ATCC and passaged
minimally prior to completing these experiments. Cell
lines were maintained as suggested by the ATTC. Cell
lines were maintained in either RPMI or DMEM sup-
plemented with 10% fetal bovine serum (all from Life
Technologies). Cells were seeded at a density 50,000 cells/
ml in the wells of a 6-well plate (Corning) in triplicate for
each time point. At each time point cells were trypsinized
and viable cells were counted with a hemocytometer using
Trypan Blue exclusion as a marker of cell viability. Relative
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relative to control at each time point.
Statistical analysis
Survival analysis and Log-rank tests were used to evaluate
survival differences between patient subgroups. We used
10 year distant metastasis free survival (DMFS) or disease
free survival (DFS) as the clinical endpoint for these stud-
ies, and log-rank tests to detect differences in survival. T-
test were used to compare means for 2-group comparisons,
whereas ANOVA followed by Dunnett’s multiple compari-
son test was used to compare means for 3 or more groups.
Tests were two-sided and a p-value of 0.05 or less was con-
sidered statistically significant.
Results
Identification of estrogen independent genes and distinct
subgroups of ER + breast cancer
The goal of this study was to enable classification of ER +
breast tumors on the basis of genes whose expression is
related to the estrogen independent biology of ER +
tumors. To this end, we took advantage of the gene ex-
pression profiles of 58 ER + breast tumors biopsied from
post-menopausal women before and after treatment with
Letrozole (n = 116, [7]). Because letrozole treatment in-
duces estrogen deprivation in tumors of post-menopausal
women, we hypothesized that genes whose expression
showed minimal variation after letrozole treatment could
be considered to be expressed independent of estrogen.









Figure 1 Discovery of estrogen independent genes and subgroups. A) Ex
within scores for all probe sets. C) NMF consensus analysis of discovery cohort i
analysis of the training cohort stratified into the 6 subgroups. E) Distant metasta
subgroups. F) Comparison of pre/post 5 year survival in tamoxifen treated subguseful to identify subtypes of ER + breast tumors, we cal-
culated between/within (b/w) scores for each probe set,
which were measurements of probe set variation observed
between different primary tumors relative to the variation
observed within paired samples pre- and post-treatment.
In this fashion, probe sets with high b/w scores showed
greater variation between different primary tumors than
between treatment paired tumor samples, whereas genes
with low b/w scores showed greater variation within treat-
ment paired tumors samples than between different tu-
mors. Therefore, probe sets with high b/w scores were
likely not influenced by estrogen deprivation and also
showed variable expression among the different tumors
prior to treatments, suggesting that they are related to dif-
ferences in the estrogen independent biology of tumors
(Figure 1A). We selected the top (highest b/w scores)
1,000 estrogen independent probe sets (893 genes) for fur-
ther analysis (Figure 1B, Additional file 1: Table S1).
To investigate whether the expression of the estrogen in-
dependent probe sets could capture the phenotypic com-
plexity of ER + breast tumors we completed unsupervised
clustering using non-negative matrix factorization (NMF)
[17]. NMF is an efficient method to identify molecular pat-
terns that is readily applicable to gene expression data, and
therefore can be used as a powerful means for class discov-
ery. In short, NMF identifies metagenes, or distinct gene
expression patterns, which are used to determine the opti-
mal value for k, where k represents the number of sample
subgroup clusters by calculating a cophenetic co-efficient
for each value of k. In short, we applied NMF (for k = 2-10)C
K=6
F Subgroup #3 – Tamoxifen
perimental strategy to identify estrogen independent genes. B) Between/
dentifies 6 subgroups of ER + breast tumors. D) Disease free survival
sis free survival analysis of the training cohort stratified into the 6
roup #3 patients.
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breast tumors (GSE6532, 133A arrays, [19] filtered such
that only the 1,000 estrogen independent probe sets were
used for class identification. This data set optimally fell into
6 clusters, designated subgroups 1–6 (Figure 1C). More-
over, NMF on an additional independent data set of 298
ER + breast tumors (GSE17705, [10]) using the same 1,000
estrogen independent probe sets also suggested that these
patients were also optimally stratified into 6 subgroups
(Additional file 2: Figure S1). Hence, we concluded that on
the basis of the expression of estrogen independent genes,
ER + breast tumors can be categorized optimally into 1 of
6 ER independent subgroups.
To learn whether these groups might encompass disease
with different clinical outcomes we compared DFS
(Figure 1D, *p < 0.05, Log-rank test) and DMFS (Figure 1E,
*p < 0.05, Log-rank test) among the various subgroups.
Interestingly, some subgroups displayed excellent long
term outcomes, whereas other groups did not. For ex-
ample, 10 year DMFS in subgroup 5 patients was 88%,
whereas in subgroup 4 patients it was 48%. All patients
comprising the various subgroups were uniformly chemo-
therapy naïve, suggesting that these differences in survival
are likely related to the natural progression of their dis-
ease, rather than influenced by response to chemotherapy.
Interestingly, in tamoxifen treated subgroup #3 (n = 27)
patients we observed that the majority of DMFS events
occurred after 5 years (Figure 1F), the time at which most
patients cease tamoxifen treatment, possibly suggesting
that these patients would have benefited from tamoxifen
treatment beyond 5 years. Unfortunately, this dataset only
comprised 8 subgroup #3 patients who did not receive
tamoxifen, making the complimentary analysis in tamoxi-
fen naive patients impractical.
Subgroups are independent of the molecular subtype of
breast cancer
Significant data exists that breast tumors can be stratified
into at least 5 molecular subtypes [1,2,16]. Accordingly, we
examined whether there was an association between the 6
subgroups we identified and the 5 molecular subtypes of
breast cancer. Classification of the 262 ER + tumors used
for discovery using the PAM50 genes (43 genes present on
133A arrays), revealed that most of the tumors were classi-
fied into either the luminal A (37%) or luminal B (29%)
molecular subtypes, whereas of the remainder 16% were
normal, 8% were basal, and 10% were ERBB2 (Figure 2A,
Additional file 2: Figure S2). Among the 6 ER independent
subgroups, only subgroup #6 was strongly associated
with any of the 5 molecular subtypes of cancer, and
comprised ~82% Lum A, ~14% LumB, and ~4% Basal-like
tumors (Figure 2A). Among the 893 ER + independent
genes, only 64 overlapped with the Sorlie et al. intrinsic
genes [2], and only 1 overlapped with the 43 PAM50 genes[16], present on the 133A array (Figure 2B and C). Hence,
we concluded that the classification of ER + breast tumors
into the 6 subgroups we identified was relatively inde-
pendent of their membership in the 5 molecular subtypes
of breast cancer.
A framework for ER + breast tumor classification
To confirm that the 6 subgroups we identified were indeed
generally representative of ER + breast tumors, we investi-
gated their prevalence in an independent validation dataset
comprising 941 ER + chemotherapy-naïve breast cancer pa-
tients. Briefly, we identified a 300 probe set classifier (using
PAM, top 50 probe sets of each subgroup) to classify tu-
mors into the 6 subgroups (Figure 2A, >80% concordance
with NMF classification). Based on the expression of the
300 probe sets, we assigned each tumor comprising the
validation data set in the 6 subgroups, using PAM
(Figure 2B). Some 84% (n = 788) of the tumors in the valid-
ation set were assigned with a probability higher than 80%
of belonging to one of the 6 subgroups, demonstrating that
the classification framework is robust. Notably, the DFS
and DMFS characteristics of patients comprising the
various 6 groups were found to be highly coincident be-
tween the original (n = 262) and validation (n = 941) co-
horts (Figure 3C and D, Additional file 2: Figure S3,
Correlation: 0.89, *p < 0.05). For instance, 10 year DMFS
was lowest in subgroup 4 for both the original and valid-
ation datasets. Similar to observations made in our train-
ing cohort, we observed that patients with subgroup #3
tumors experienced the majority of DMFS events after
5 years (Additional file 2: Figure S4). To learn whether this
phenomenon was related to tamoxifen treatment, we sub-
divide subgroup #3 patients into tamoxifen treated (n =
94) and tamoxifen naive patients (n = 32) and compared
pre/post 5 year DMFS survival in each group. Whereas
there was no difference between pre/post 5 year DMFS in
tamoxifen naive patients, there was a significant differ-
ent pre/post 5 year DMFS in tamoxifen treated patients
(Figure 3E and F, No tamoxifen, HR: 0.82, p = 0.8, Tamoxi-
fen, HR: 0.26, *p < 0.05). These results might be inter-
preted to suggest that in subgroup #3 tumors early relapse
is prevented by tamoxifen, albeit relapses resume after the
completion of a patient’s tamoxifen regimen. Indeed, clin-
ical trials examining the use of tamoxifen for a period
greater than 5-years demonstrate that a subset of ER +
breast cancer patients benefit from such treatment [20].
Hence, patients with subgroup #3 tumors might represent
those who benefit from extended tamoxifen treatment.
As additional validation, we investigated the preva-
lence of the 6 subgroups in the TCGA breast data set,
which comprised 801 ER + breast tumors [4]. Using the
PAM classifier described above, the mean probability for
classification was 86%, and more than 70% (n = 580) of
the tumors in the TCGA set were assigned a probability








































Figure 2 6 subgroups classification is independent of tumor molecular subtype membership. A) Subgroup/Subtype assignment of each
tumor. B) Overlap between ER independent genes and intrinsic genes. C) Overlap between ER independent genes and PAM50 genes.
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(Additional file 2: Figure S5 A&B). Hence, this extra val-
idation data set provides additional evidence for the ro-
bustness of the classification framework.
Taken together with our previous data, these results
demonstrate that the 6 identified subgroups of ER +
breast tumors can be reproducibly identified in inde-
pendent patient cohorts and provide a clinically relevant
means of classifying ER + breast tumors.
ER + subgroups enable predictive modeling of anti-cancer
drug sensitivity
As described above, the established framework allows clas-
sification of ER + breast tumors into 1 of 6 subgroups based
on patterns in estrogen independent gene expression. We
first tested whether this framework could be extended to
classify ER + breast tumor cell lines into the same sub-
groups. We accessed previously described breast tumor cell
line gene expression datasets [6,13] and classified ER +
breast tumor cell lines into the 6 subgroups. Among 24
ER + breast tumor cell lines, 5 of the 6 subgroups were rep-
resented by at least 4 cell lines, thus providing experimental
models for these subgroups (Figure 4A, Additional file 1:
Table S2). We sought to identify compounds with sub-
group specificity for the most aggressive subgroups based
on our analyses of DMFS in the patient cohorts. Although
patients with subgroup #4 tumors experienced the worst
outcome, we failed to identify any subgroup #4 cell lines.
Hence we focused our efforts on the second most aggres-
sive subgroup, which was subgroup #1. We observed that
subgroup #1 tumors tended to over-express genes involved
in the repair of double stranded (ds) DNA breaks, includ-
ing RAD50 [21] and BARD1 [22], suggesting that subgroup
#1 tumors possess a ‘dsDNA break’ phenotype and may
be hypersensitive to agents that induce dsDNA breaks
(Figure 4B). We also examined RAD50 and BARD1 ex-
pression in cell lines stratified by subgroup, however this
analysis was inconclusive likely owing to the fact that most
subgroups comprised very few lines (Additional file 2:
Figure S6A). Subgroup #1 cell lines were hypersensitive toetoposide, a potent and specific inducer of dsDNA breaks
[23] (Figure 4C). Specifically, we compared the relative
growth (to control) of 3 subgroup #1 cell lines and 3 cell
lines belonging to other subgroups over 72 hours of treat-
ment with 200nM etoposide. After 72 hours, relative
growth was significantly lower in subgroup #1 cell lines
(34% of control) compared to the relative growth of non-
subgroup #1 cell lines (79% of control)(Figure 4D, *p =
0.008, t-test). To confirm these findings, we obtained breast
tumor cell line drug sensitivity data that was previously re-
ported by Heiser et al. in 2012 [6], for 18 cell lines that
were also present within the cell line gene expression data
set. Similar to our previous observations, we observed the
subgroup #1 cell lines were generally the most sensitive to
etoposide (Figure 4E-i. The mean –log10(IC50) of subgroup
#1 cell lines was significantly lower than cell lines belong-
ing to other subgroups (Figure 4E-ii, *p = 0.02, t-test).
To extend these findings, we looked for over-expression
of other actionable targets with subgroup selective expres-
sion among the 6 subgroups (Additional file 2: Figure S6).
IGF2 was over-expressed in subgroup 2 tumors, implicat-
ing IGF signaling as a therapeutic target in subgroup#2 tu-
mors. Interestingly, subgroup #3 tumors significantly over-
expressed the angiotensin receptor 2 (AGTR2). Whereas
AGTR2 hasn’t been a target for cancer drug development,
it has been a successfully exploited target for the develop-
ment of hypertension drugs [24]. Other notable targets in-
cluded over-expression of the anti-apoptotic protein BCL2
in subgroup #3 tumors, and the immune-modulatory tar-
get CTLA4 in subgroup #5 tumors. In each case, approved
therapeutics exist or are under development that target
these highlighted over-expressed genes. These observed
patterns could potentially be used to target therapies in
ER + breast cancer patients contingent on the subgroup
membership of their tumor.
Discussion
Substantial molecular heterogeneity exists among ER +
tumors, which isn’t adequately captured by either histo-





Figure 3 The 6 subgroups are reproducibly identifiable. A) Subgroup assignment for NMF or 300 probe set PAM classifier (83% concordance).
B) PAM assignment of validation cohort tumors into the 6 subgroups. C) Disease free survival among the validation cohort patients stratified by subgroup.
D) Distant metastasis free survival among the validation cohort patients stratified by subgroup. E) Comparison of pre/post 5 year survival in tamoxifen
naive subgroup #3 validation cohort patients. F) Comparison of pre/post 5 year survival in tamoxifen treated subgroup #3 validation cohort patients.
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of classifying ER + tumors, and reproducibly identified 6
subgroups of ER + tumors based on the expression of estro-
gen independent genes. Notably, we also observed survival
and treatment sensitivity differences among the 6 sub-
groups. Hence, our data suggests that patient subgroup
membership may be a useful tool for guiding treatment of
ER + breast cancer patients.
Briefly, the subgroup identification strategy was highly
similar to that originally described by Perou et al. in 2000[1]. Whereas Perou et al. employed an unsupervised clus-
tering approach with intrinsic genes in unselected breast
tumors, we employed unsupervised clustering with estro-
gen independent genes in breast tumors selected for ER
positivity. For this experiment we analysed gene expres-
sion profiling data from 58 ER + tumors biopsied from
post-menupausal women before and after treatment with
letrozole [7]. We hypothesized that genes whose expres-
sion showed minimal variation after letrozole treatment
could be considered to be expressed independent of
AC D E
B
Figure 4 Subgroup specific response to anti-cancer compounds. A) Cell line subgroup assignment based on PAM classifier. B) Expression of
RAD50 and BARD1 in the 6 subgroups subgroups. C) Relative growth analysis of subgroup 1 and non-subgroup #1 cell with or without 200nM
etoposide. D) Relative growth at 72 hours for subgroup #1 and other cell lines reveals marked etoposide selectivity for subgroup #1 cell lines.
E) Cell line sensitivity to etoposide from the Heiser et al. published dataset (*p = 0.02, t-test).
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on this assumption. However, many breast cancer patients
are pre-menopausal and receive different endocrine therap-
ies for breast cancer treatment, namely tamoxifen. It is un-
clear whether the definition of estrogen independent genes
we propose here would be different in pre-menopausal pa-
tients, or patients treated with alternate endocrine agents,
and these possibilities represent intriguing avenues for
future research. We note however, that subgrouping ER +
tumors based on estrogen independent gene expression
was both robust and reproducible in cohorts of tumors that
included pre-menopausal patients as well as those treated
with tamoxifen, suggesting that our approach is broadly
applicable.
There remain several limitations of the work reported
herein. All of our conclusions are based on the analysis
of retrospective data, which limits its clinical value. Wevalidated the occurrence, and clinical attributes, of the 6
subgroups in relatively large independent cohorts, how-
ever a true estimate of the clinical usefulness of the 6 sub-
group classification for ER + breast cancers would require
additional validation in clinical trial samples, as well as
completion of a prospective clinical trial examining the
capacity of the classification to guide therapy. In addition,
it isn’t clear if subgroup classification would add meaning-
ful clinical information beyond that obtained from existing
prognostic tests designed for ER + tumors, such as Onco-
typeDX® [25]. For example, a relevant question that re-
mains is whether the good prognosis subgroups identified
here (subgroups 2,5&6) experience similarly excellent sur-
vival to the low risk group identified by OncotypeDX®.
Additionally, it isn’t clear if the relationship between pa-
tient outcome and subgroup assignment is a consequence
of subgroup association with natural progression of breast
Hallett and Hassell BMC Cancer 2014, 14:871 Page 8 of 9
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Many of the patients obtained from publically available
sources had incomplete clinical annotations, and they
comprise a mixture of patients that received no adjuvant
therapy, or adjuvant tamoxifen, likely lasting for 5 years.
Based on these data it is difficult to discern how differ-
ences in extent or choice of endocrine therapy might in-
fluence the relationship between patient outcome and
subgroup membership. Hence, although our data suggests
the 6 subgroup classification of ER + breast cancer may be
useful for guiding therapy in patients, many additional val-
idation experiments are required to confirm our findings.
Conclusion
Ultimately, we propose that the 6 subgroups described
here provide a strategy for improved understanding and
treatment of ER + breast tumors. We demonstrate that
the subgroups are unique and independent of the mo-
lecular subtypes of cancer, and provide a clinically rele-
vant means of tumor classification. We anticipate that
subgrouping will provide a framework to both guide op-
timal use of existing therapeutics, as well as gain insight
into biological processes that represent relevant targets
for development of the next generation of experimental
therapies.
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